Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis (MS and EBV-CTL)
An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: David LAPLAUD, Doctor
- Phone Number: + 33 (0)2 40 16 52 00
- Email: david.laplaud@univ-nantes.fr
Study Locations
-
-
-
Nantes, France
- Recruiting
- University Hospital
-
Contact:
- David LAPLAUD, Doctor
- Phone Number: + 33 (0)2 40 16 52 00
- Email: david.laplaud@univ-nantes.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18<Age≤45 years
Patients with :
- A clinically isolated syndrome (first acute or sub acute neurological event consistent with demyelination [i.e. optic neuritis, spinal cord syndrome, brainstem/ cerebellar syndrome])
- And a MRI scan showing dissemination of MRI lesions in space based on 2017 McDonald criteria At least 1 lesion detected in 2 or more following locations (sites) periventricular, cortical or juxtacortical, infratentorial, spinal cord
- With a possible dissemination in time based on the revised McDonald cirteria and evicenced on simultaneous detection of one Gadolinium (Gd) enhancing and non-Gd enhancing lesions
- Or demonstration of CSF-specific oligoclonal bands (OCBs)
- EDSS Score <3
- Patients covered by health care insurance (social security)
- Written informed consent obtained.
- Onset of symptoms occurring within 60 days of inclusion
- Patients with HIV, HTLV, Hepatitis B, C Syphilis testing negative within 30 days
- Positive EBV serology
- White blood cell count (Leukocytes) > 750/mm3
- Negative pregnancy test
Exclusion Criteria:
- Patients with clinically definite multiple sclerosis
- Patients known to have HIV, HTLV Hepatitis A, B, C or Syphilis infections or patient with active uncontrolled systemic bacterial, viral, parasitic or fungal infections.
- Patients with white blood cell count (Leukocytes) < 750/mm3
- Pregnant or breast feeding women
- Patient with childbearing potentiel refusing efficient contraceptive method
- Patients wishing to be pregnant during the course of the study
- Patients under legal guardianship
- Concomitant participation of any other trial
- Patients with mental or psychiatry condition unable to understand the trial
- Patients with any medically unstable condition or any health conditions that may impact the safety of the patient as determined by the investigator or patient with any stable condition treated with immunotherapy
- Patients with a history of cancer within 5 years or progressive cancer except for basal or cell skin lesions surgically excised and cured, in situ cervical cancer
- Patients unable to comply with protocol.
- Contraindication for MRI or/and any known history of hypersensitivity to contrast medium
- Patients currently treated with immunosuppressive drugs including oral or systemic corticosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cellular therapy with EBV specific autologous CTL infusion
|
CTL infusions at D0, M3 and M6
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RC14_0359
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.